HK Stock Market Move | INSILICO (03696) surged nearly 8% and reached a cooperation agreement with SK Biopharmaceuticals on AI-driven drug research and development. The potential total transaction amount exceeds $2.5 billion.

INSILICO (03696) rose nearly 8%, as of the time of writing, it has risen by 6.15% to 42.48 Hong Kong dollars, with a turnover of 98.74 million Hong Kong dollars. On the news front, according to INSILICO's official WeChat message, on June 22, INSILICO and SK Biopharmaceuticals, a leading biotechnology innovator headquartered in South Korea focused on pioneering drug research, jointly announced that they have reached an AI-driven drug development cooperation agreement on the eve of the BIO 2026 International Conference. The two parties will focus on the field of neuroimmune diseases and leverage AI technology to discover innovative drug candidates. According to the agreement, INSILICO will utilize its proprietary Pharma.AI platform covering target validation, molecule generation, and molecule optimization, combined with its expertise in preclinical drug discovery, to focus on the discovery, design, and optimization of novel candidate drugs for neuroimmune indications. It is worth mentioning that INSILICO will be eligible to receive up to $18 million in upfront payments and near-term milestone payments. In addition, the potential total transaction value of this collaboration exceeds $2.5 billion, covering development, regulatory, and commercial milestones payments, as well as single-digit percentage royalties on net sales post-commercialization. In terms of the potential total transaction value, this is the largest collaboration INSILICO has reached with partners in the Asia-Pacific region to date.